Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 4(3)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05036434Phase 2Active Not Recruiting

Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma

Role: collaborator

NCT03717194Phase 3Completed

Effect of Ertugliflozin on Cardiac Function in Diabetes

Role: collaborator

NCT03039543Phase 4Completed

Neuromuscular Blockade During Transurethral Resection of Bladder Cancer

Role: collaborator

NCT01965067Phase 4Completed

Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex

Role: lead

NCT00699322Phase 4Unknown

Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress

Role: collaborator

All 5 trials loaded